Letrozole Uses for Breast Cancer, Fertility, and PCOS

Letrozole is an aromatase inhibitor that works by blocking the enzyme responsible for producing estrogen, and its uses span a surprisingly wide range of medical fields. Originally developed and approved for treating hormone-receptor-positive breast cancer in postmenopausal women, letrozole has since become a first-line fertility drug for ovulation induction, an emerging treatment for male infertility, and an investigational therapy for conditions from endometriosis to short stature in boys. Its mechanism is straightforward, but the downstream effects of estrogen suppression ripple through enough body systems that the drug keeps finding new clinical niches.

How Letrozole Works

Letrozole belongs to the third generation of aromatase inhibitors, a class of drugs that shut down the body’s production of estrogen by targeting the aromatase enzyme. What makes letrozole stand out, even among its peers, is how thoroughly it does the job. It produces near-complete inhibition of aromatase in peripheral tissues and suppresses estrogen more effectively than other aromatase inhibitors, all without interfering with other hormone-production pathways.¹ In postmenopausal women, whose ovaries have stopped making estrogen, the aromatase enzyme in fat, muscle, and other tissues is the main remaining estrogen source. In premenopausal women and in men, blocking aromatase triggers a different chain of hormonal events that clinicians have learned to exploit for fertility and growth purposes.

Breast Cancer in the Early Stages

The largest body of evidence for letrozole involves early-stage, hormone-receptor-positive breast cancer in postmenopausal women. The landmark BIG 1-98 trial compared five years of letrozole against five years of tamoxifen, the older standard. After roughly four years of follow-up, letrozole reduced the risk of disease recurrence by about 18%, and the benefit was especially pronounced for cancers that had already started to spread to distant sites, where the risk dropped by roughly a quarter.² An updated analysis with longer follow-up confirmed the advantage, with five-year disease-free survival estimates of about 84% for letrozole versus about 81% for tamoxifen.³

That gap may sound modest in percentage terms, but for the tens of thousands of women diagnosed each year, an 18–19% relative reduction in recurrence risk translates to a meaningful number of women who stay cancer-free. And because letrozole was particularly effective against distant metastases, the benefit is not just about local recurrences caught on a scan but about preventing the kind of spread that becomes life-threatening.

Extended Adjuvant Therapy After Tamoxifen

Many women with hormone-receptor-positive breast cancer finish five years of tamoxifen and face a lingering question: should they keep going with some form of endocrine therapy? The MA.17 trial addressed this by randomizing women who had already completed about five years of tamoxifen to either letrozole or a placebo. At a median follow-up of about two and a half years, letrozole cut the risk of recurrence or new contralateral breast cancer by roughly 42%, and among women whose original tumors had involved lymph nodes, overall survival improved too.⁴

Whether to stretch treatment even further, to a full decade of aromatase-inhibitor therapy, is less clear-cut. A trial that looked at extending letrozole to ten total years found a disease-free survival benefit (about 95% versus 91% at five years) but no improvement in overall survival, plus more bone-related side effects.⁵ A separate trial, B-42, similarly found that adding five years of letrozole after an initial five years of aromatase-inhibitor-based therapy produced only a borderline improvement in disease-free survival that did not cross the pre-specified statistical threshold, leading the authors to recommend careful weighing of risks and benefits rather than blanket continuation.⁶ The upshot: extended letrozole clearly has a role after tamoxifen, but the further you push past a decade of total endocrine therapy, the more you trade uncertain gains against real side effects.

One practical wrinkle for women on long-term therapy: the SOLE trial tested whether taking periodic breaks from letrozole (an intermittent schedule) was as effective as continuous dosing. It found no benefit from the intermittent approach, though the results were interpreted as supporting the safety of temporary breaks for women who need them for quality-of-life reasons.⁷

Advanced and Metastatic Breast Cancer

When breast cancer has spread beyond the original tumor, letrozole serves as the hormonal backbone of first-line combination therapy. The PALOMA-2 trial paired letrozole with palbociclib, a CDK4/6 inhibitor, in women with estrogen-receptor-positive, HER2-negative advanced breast cancer. Women receiving the combination went a median of roughly 25 months before their disease progressed, compared with about 14.5 months for women on letrozole alone.⁸ An earlier phase 2 trial had already shown a doubling of progression-free survival with the combination, with medians of about 20 versus 10 months.⁹

This combination has become standard of care for first-line treatment, and letrozole pairs with other CDK4/6 inhibitors too. Still, not every patient responds equally, and resistance can develop. In metastatic hormone-receptor-positive breast cancer, mutations in the ESR1 gene are a common reason tumors stop responding to estrogen deprivation.¹⁰ These mutations effectively let the estrogen receptor activate itself even without estrogen, rendering aromatase inhibitors less useful. Detecting ESR1 mutations through blood-based liquid biopsies has become an increasingly important tool for deciding when to switch therapy.

Ovulation Induction and PCOS

Perhaps the most consequential expansion of letrozole’s use has been in fertility treatment, specifically for women with polycystic ovary syndrome (PCOS) who are not ovulating regularly. For decades, clomiphene citrate was the default first-line drug, but letrozole has overtaken it in many guidelines. The pivotal trial that shifted practice enrolled 750 women with PCOS and found that letrozole produced a higher cumulative live-birth rate than clomiphene: about 28% versus 19%. The cumulative ovulation rate was also higher with letrozole, at roughly 62% of treatment cycles compared with about 48%.¹¹

Smaller trials have largely confirmed the pattern. One trial found pregnancy rates of 29% with letrozole versus about 15% with clomiphene, with letrozole also producing a higher live-birth rate and more single-follicle development, which lowers the chance of twins.¹² Another found comparable ovulation rates between the two drugs but better endometrial response and pregnancy rates with letrozole.¹³

The reason letrozole works well here comes back to its mechanism. By temporarily suppressing estrogen, it tricks the brain’s feedback system into ramping up follicle-stimulating hormone, which nudges the ovaries to develop and release a mature egg. Because letrozole clears the body quickly, the endometrial lining is not exposed to the anti-estrogen effects seen with clomiphene, which can thin the lining and make implantation harder.

Letrozole in IUI and Unexplained Infertility

Beyond PCOS, letrozole is commonly paired with intrauterine insemination (IUI) for couples with unexplained infertility or mild male-factor issues. A systematic review and meta-analysis comparing letrozole to clomiphene in IUI cycles concluded that letrozole may improve dominant follicle development and reduce miscarriage rates.¹⁴ A randomized trial of an extended letrozole regimen (given over more days than the standard five-day course) versus clomiphene in IUI found significantly higher per-cycle and cumulative pregnancy rates with the extended approach.¹⁵

A smaller pilot trial that randomized women with unexplained or mild male-factor infertility to letrozole-IUI versus natural-cycle IUI found similar live-birth rates of about 24% and 20% respectively, though the study was too small to draw firm conclusions.¹⁶ The takeaway is that letrozole’s benefit is most clearly established in anovulatory conditions like PCOS. In unexplained infertility, the evidence is encouraging but less definitive.

Safety for Babies Conceived with Letrozole

Early on, a single abstract raised alarms about possible birth defects with letrozole-assisted conception, a report that was later widely criticized for flawed methodology. The reassuring evidence has accumulated steadily since then. A systematic review and meta-analysis covering nearly 4,700 babies found an overall rate of congenital malformations of about 2.2% among letrozole-conceived infants, with no increase compared with clomiphene-conceived infants in randomized trials.¹⁷ A large Australian cohort study found major congenital anomalies in about 1.9% of letrozole cycles and 1.5% of natural cycles, a non-significant difference.¹⁸ That 2% range is in line with background rates in the general population, and a Canadian review concluded that letrozole for ovulation induction has not been associated with an increased risk of birth defects.¹⁹

Endometriosis

Endometriosis is an estrogen-dependent condition, making aromatase inhibition a logical therapeutic strategy. In a pilot study of 10 women with endometriosis and chronic pelvic pain who had not responded to other treatments, a combination of letrozole and norethindrone acetate (a progestin) achieved marked reduction in visible and biopsy-confirmed endometriosis in all patients, with significant pain relief in nine out of ten.²⁰ A randomized trial comparing letrozole plus norethisterone acetate to letrozole plus triptorelin (a GnRH agonist) found that both regimens significantly reduced non-menstrual pelvic pain and painful intercourse during treatment.²¹ A separate case series using letrozole with a desogestrel-only pill in women with advanced-stage endometriosis reported significant improvements in pain during menstruation and intercourse.²²

In all these studies, letrozole was combined with a progestin or another hormonal agent rather than given alone. That is by design: using letrozole by itself in premenopausal women would trigger a compensatory surge in ovarian estrogen production, defeating the purpose. The progestin suppresses ovulation and provides the hormonal control needed for the aromatase inhibitor to work.

Male Infertility

In men, a fraction of testosterone is normally converted to estrogen by aromatase. When that ratio gets out of balance, too much estrogen relative to testosterone, sperm production can suffer. Letrozole shifts the ratio back by blocking the conversion. A randomized placebo-controlled trial in men with moderate-to-severe oligoasthenoteratozoospermia (a combination of low count, poor motility, and abnormal morphology) found that letrozole significantly raised testosterone, increased follicle-stimulating hormone and luteinizing hormone, and improved sperm count and progressive motility compared with placebo.²³ A smaller head-to-head comparison of letrozole and anastrozole in infertile men with low testosterone-to-estrogen ratios confirmed that both aromatase inhibitors improved hormonal and semen parameters.²⁴

This remains an off-label use, and the evidence base is still growing. But letrozole has emerged as a plausible treatment option for a subset of men whose infertility has a hormonal component, particularly those with low testosterone and relatively high estrogen levels.²⁵

Height Augmentation in Boys

In growing boys, estrogen (produced locally in the growth plates from testosterone via aromatase) is the signal that eventually fuses the growth plates and stops height gain. Blocking that conversion with letrozole theoretically delays fusion and allows more time for growth. The concept has been tested in boys with constitutional delay of growth and puberty, and results have been mixed. One study found that treated boys reached an average adult height about 2 centimeters taller than controls, a statistically significant difference.²⁶ A Chinese observational study of short pubertal boys found that after one year, 88% had increased predicted adult heights, with average predicted height rising by several centimeters.²⁷

However, a Finnish placebo-controlled trial in pre-pubertal and early-pubertal boys found no difference in adult height between letrozole and placebo groups.²⁸ Timing and pubertal stage seem to matter. Letrozole’s effect on height may depend on whether a boy has already entered puberty, when testosterone levels are rising and there is more substrate for aromatase to convert. In pre-pubertal boys with little testosterone in circulation, blocking aromatase has less hormonal material to work with. This remains an investigational use, and long-term safety data in children are limited.

Side Effects Worth Knowing About

Because letrozole suppresses estrogen so effectively, its side-effect profile reads like a catalog of what estrogen normally protects. Joint pain is probably the most common complaint. About a quarter of postmenopausal women on aromatase-inhibitor therapy report arthralgia, though trial data show the symptoms are mostly mild to moderate and lead to treatment discontinuation in only a small percentage of patients.²⁹ Exercise, physical therapy, and standard pain relief measures can help manage it.³⁰

Bone loss is a more serious concern for long-term users. Aromatase inhibitors lower circulating estrogen to nearly undetectable levels in postmenopausal women, which predisposes them to accelerated bone loss and increased fracture risk.³¹ In the BIG 1-98 bone-density substudy, all aromatase-inhibitor regimens, whether letrozole alone or sequenced with tamoxifen, reduced bone mineral density.³² Bone-protective drugs like zoledronic acid have been shown to counteract letrozole-induced bone loss, and guidelines typically recommend baseline and periodic bone-density monitoring for women starting aromatase-inhibitor therapy.³³

For short-course use in fertility treatment, lasting only five to ten days per cycle, these long-term skeletal effects are not a practical concern.

Cardiovascular Considerations

The cardiovascular picture of letrozole versus tamoxifen is a tale of trade-offs rather than a clear winner. In the BIG 1-98 trial, letrozole monotherapy was associated with a higher risk of ischemic heart disease compared with tamoxifen monotherapy. But tamoxifen came with a significantly higher risk of blood clots.³⁴ Sequential regimens, where patients took one drug followed by the other, produced intermediate risk for both outcomes. A study on endothelial function found that tamoxifen users had better arterial dilation and lower total cholesterol than letrozole users, though letrozole users had lower triglycerides, and letrozole users’ vascular measures were no worse than those of women taking neither drug.³⁵

Lipid monitoring is advisable during long-term letrozole therapy. A substudy of the MA.17 trial found significant increases in total cholesterol, LDL cholesterol, and particularly lipoprotein(a) after five years of letrozole following five years of tamoxifen, with more than half of women developing clinically elevated lipoprotein(a) levels.³⁶

Why Some People Respond Differently

Letrozole is broken down primarily by the liver enzyme CYP2A6, and genetic variation in this enzyme influences how much active drug circulates in a person’s blood. A genome-wide association study identified a variant near the CYP2A6 gene that explained about 13% of the variability in steady-state letrozole concentrations.³⁷ People who carry reduced-function versions of CYP2A6 end up with higher letrozole levels in their blood.³⁸ Interestingly, though, those higher levels were not linked to worse joint pain in breast cancer patients, which suggests the relationship between drug level and side effects is not straightforward.

For fertility applications, one study of CYP2A6 variants in women with PCOS found no significant difference in ovulation response or pregnancy rates between women carrying different genotypes.³⁹ That may be because the short courses used for ovulation induction produce sufficient aromatase inhibition regardless of modest differences in metabolism. In cancer treatment, where the drug is taken daily for years, differences in blood levels could theoretically matter more, but clinical trials have not yet established whether genotype-guided dosing would improve outcomes.

Off-Label Use by Steroid Users

Letrozole has a following in bodybuilding and anabolic-steroid communities, where it is used to counteract the estrogen-related side effects of steroid use. When men inject supraphysiological doses of testosterone, the excess is partly converted to estrogen by aromatase, which can cause breast tissue growth, water retention, and other unwanted effects. An analysis of online forums found that aromatase inhibitors were commonly used alongside steroids specifically to fight against the conversion of androgens to estrogen.⁴⁰ This is unsupervised self-medication, often at doses and durations never studied in clinical trials, and carries the risk of suppressing estrogen to dangerously low levels, which can damage bone health, lipid profiles, and mood.

Emerging Use in Ovarian Cancer

Most of letrozole’s oncology evidence is in breast cancer, but early work is extending to other hormone-sensitive malignancies. Low-grade serous carcinoma of the ovary is a rare subtype that often expresses hormone receptors, and epidemiological data have suggested letrozole could slow its progression. A multicenter phase III trial is now comparing letrozole to standard chemotherapy for this cancer, and preliminary findings indicate letrozole is well tolerated in this context.⁴¹ If efficacy data confirm what retrospective studies have hinted, letrozole could offer an oral, low-toxicity alternative to intravenous chemotherapy for a cancer that tends to recur and requires long-term management.

Cost and Accessibility

Letrozole went off patent years ago, and generic versions are widely available, which has helped it spread into fertility clinics in resource-limited settings. In its original breast-cancer role, a cost-effectiveness analysis estimated that letrozole produced about 0.4 additional quality-adjusted life years compared with tamoxifen at a cost well within conventional willingness-to-pay thresholds.⁴² For fertility use, the drug’s low price and oral dosing make it far more accessible than injectable gonadotropins, which can cost ten to fifty times as much per cycle. This economic advantage is one reason letrozole has been adopted quickly in low- and middle-income countries where injectable fertility drugs are prohibitively expensive.